Any current/future new fundraising through debt or equity?

There is no explicit mention of any new fundraising through debt or equity in the provided transcript. The company is focused on reducing net debt by INR 100 to 200 crores annually through free cash flow generation. Most large CAPEX (e.g., French facility, digital transformation) is behind them, and future CAPEX will be based on proper business cases with customer commitments. The management emphasizes generating free cash flow and avoiding sales that reduce profitability just to increase revenues. Co-investment agreements with customers, such as the Japanese innovator investing EUR 25 million

Any current/future capex/capital investment/strategic investment?

FY ‘26 CAPEX guidance is approximately INR 250 crores to INR 300 crores (EUR 25-30 million). Maintenance CAPEX is around INR 170-180 crores; the remainder is growth CAPEX including digital transformation initiatives. Large CAPEX for the French entity is mostly behind; future CAPEX will focus on expansion based on confirmed business cases. Co-investment of EUR 25 million by a Japanese customer for a specific project; infrastructure investment is a core investment paid by the client. Additional investments are planned in product expansion projects in Europe and India. Focus on CAPEX only when th

Future growth expectations in sales/revenue/volumes?

The company targets a low double-digit revenue growth, aiming for a CAGR of 12% to 15% over the next 3 to 5 years. (Page 10) India CRAMS business is expected to grow by 15% to 20% in FY ‘26. (Page 9) The Quats and Generics business is expected to grow between 5% to 10%. (Page 9) Peak revenue from India assets could reach around INR 800 crores within 2 to 3 years. (Pages 13-14) Bavla site's quarterly revenue is anticipated to reach around INR 100 crores in the later part of FY ‘26. (Page 15) EBITDA targeted at INR 550 crores to INR 570 crores in FY ‘26, with potential for higher margins than 20

Future growth expectations in earnings/operating earnings/profits/EPS?

EBITDA for FY '26 is expected between INR 550 crores to INR 570 crores, targeting a 20% margin. Revenue growth target is low double digits annually, aiming for sustained profitability alongside revenue increase. Operating profit (EBITDA) is projected to reach around INR 750 crores within the next 2 to 3 years. ROCE is currently low (~2%) but expected to improve to double digits (13%-15%) within 3 years due to ramp-up of various business entities. Free cash flow generation is prioritized with a plan to reduce net debt by INR 100-200 crores annually. Profit after tax (PAT) should impro

Current/ Expected Orderbook/ Pending Orders?

The transcript does not explicitly mention the current or expected order book or pending orders by a specific value. However, the discussion indicates a positive outlook on upcoming projects, with a focus on early-phase and late-phase (Phase IIb and Phase III) projects. The company is investing in market intelligence to identify new opportunities and potentially become a secondary supplier for risk mitigation. There is a mention of strong interest and investment in the CRAMS business and API development with expected growth. A co-investment of EUR 25 million with a Japanese innovator was noted

IN US

Sale is live|00:00:00left today

Dishman Carbogen Amcis LtdQ1 FY25Pharmaceuticals & Biotechnology

Dishman Carbogen Amcis Ltd Q1 FY25 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹173P/E: 23.1Market Cap: ₹3.0K CrSector: Pharmaceuticals & Biotechnology

Management growth scorecard

Revenue

Category 3

Margin

Category 1

Fundraise

N/A

Order

N/A

Capex

Yes

2 of 3 growth signals are positive.

Full analysis

Revenue guidance

Category 3

→The company targets a low double-digit revenue growth, aiming for a CAGR of 12% to 15% over the next 3 to 5 years. (Page 10)
→India CRAMS business is expected to grow by 15% to 20% in FY ‘26. (Page 9)
→The Quats and Generics business is expected to grow between 5% to 10%. (Page 9)
→Peak revenue from India assets could reach around INR 800 crores within 2 to 3 years. (Pages 13-14)
→Bavla site's quarterly revenue is anticipated to reach around INR 100 crores in the later part of FY ‘26. (Page 15)
→EBITDA targeted at INR 550 crores to INR 570 crores in FY ‘26, with potential for higher margins than 20%. (Page 22)
→The company is focusing on collaboration and transferring production of molecules to India for improved utilization and margin. (Pages 13-14)
→Expansion efforts include exploring new markets outside the U.S. and investing in value-added products like ADCs and conjugates. (Pages 11, 21)

Margin guidance

Category 1

→EBITDA for FY '26 is expected between INR 550 crores to INR 570 crores, targeting a 20% margin.
→Revenue growth target is low double digits annually, aiming for sustained profitability alongside revenue increase.
→Operating profit (EBITDA) is projected to reach around INR 750 crores within the next 2 to 3 years.
→ROCE is currently low (~2%) but expected to improve to double digits (13%-15%) within 3 years due to ramp-up of various business entities.
→Free cash flow generation is prioritized with a plan to reduce net debt by INR 100-200 crores annually.
→Profit after tax (PAT) should improve with decreasing interest costs and amortization, though tax rate is likely to stay around 25%-30% effective.
→Margins in Indian CRAMS business targeted at 20-25%, with overall company EBITDA margin aiming at 20% in FY '26.
→EPS growth expected in line with EBITDA and revenue growth as profitability and efficiencies improve.

3 more insights locked — sign up free to unlock

Fundraise plans

→There is no explicit mention of any new fundraising through debt or equity in the provided transcript.
→The company is focused on reducing net debt by INR 100 to 200 crores annually through free cash flow generation.
→Most large CAPEX (e.g., French facility, digital transformation) is behind them, and future CAPEX will be based on proper business cases with customer commitments.
→The management emphasizes generating free cash flow and avoiding sales that reduce profitability just to increase revenues.
→Co-investment agreements with customers, such as the Japanese innovator investing EUR 25 million, are structured with customer payments funding infrastructure rather than the company raising external funds.
→Debt costs are expected to decrease due to lower interest rates and goodwill amortization reduction.

Order book

→The transcript does not explicitly mention the current or expected order book or pending orders by a specific value.
→However, the discussion indicates a positive outlook on upcoming projects, with a focus on early-phase and late-phase (Phase IIb and Phase III) projects.
→The company is investing in market intelligence to identify new opportunities and potentially become a secondary supplier for risk mitigation.
→There is a mention of strong interest and investment in the CRAMS business and API development with expected growth.
→A co-investment of EUR 25 million with a Japanese innovator was noted, reflecting confidence from clients and a strong project pipeline.
→Revenue targets imply growing order inflows to meet EBITDA of INR 550-570 crores expected for FY ‘26, and longer-term EBITDA target of INR 750 crores in 2-3 years.

Capex plans

Yes

→FY ‘26 CAPEX guidance is approximately INR 250 crores to INR 300 crores (EUR 25-30 million).
→Maintenance CAPEX is around INR 170-180 crores; the remainder is growth CAPEX including digital transformation initiatives.
→Large CAPEX for the French entity is mostly behind; future CAPEX will focus on expansion based on confirmed business cases.
→Co-investment of EUR 25 million by a Japanese customer for a specific project; infrastructure investment is a core investment paid by the client.
→Additional investments are planned in product expansion projects in Europe and India.
→Focus on CAPEX only when there is committed revenue from customers to ensure returns.
→Capital expenditure includes upgrades at Bavla and Naroda sites to support a peak revenue potential of INR 800 crores for India assets.
→Discussions continue on alliances and strategic investments to support growth and business expansion.

How does Dishman Carbogen Amcis Ltd rank vs peers in Pharmaceuticals & Biotechnology?

Pro feature

1Dishman Carbogen Amcis Ltd

Rev 3Mar 1

See full Pharmaceuticals & Biotechnology sector rankings

Want more stocks like Dishman Carbogen Amcis Ltd?

Build an AI portfolio filtered by sector, market cap, and growth rank. Takes 2 minutes.

Build my portfolio